• Oct 5, 2026

  $100.19+0.23%

• Oct 2, 2026

  $99.96+0.31%

• Oct 1, 2026

  $99.65+0.12%

• Sep 30, 2026

  $99.53+0.02%

  Shares closed essentially flat, up 0.02%. Globenewswire carried Lantheus's announcement that CMS granted transitional pass-through status for PYLARIFY TruVu, along with a permanent HCPCS code effective October 1, 2026 [1]. Volume was 1.8x the trailing 20-session average, while the session traded in a narrow range of 0.4% of the low [2].

  • 1Globenewswire
  • 2Market data

• Sep 29, 2026

  $99.51-0.23%

• Sep 28, 2026

  $99.74+0.00%

  Shares closed unchanged at +0.00% on the day. Globenewswire carried Lantheus's announcement that the first patient had been dosed in the SPARROW Phase 2/3 registrational trial in prostate cancer [1]. The study advances development of the company's investigational GRPR-targeted PET imaging program [1].

  • 1Globenewswire

• Sep 25, 2026

  $99.74+0.02%

Closing prices for LNTH. Summaries describe past sessions only and are not advice, a forecast or a recommendation.

Headlines are published by third parties and linked as reported. Amaltash does not endorse or verify them.